B iotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s full-year revenue guidance of $620 ...

We are grateful to work with Arc and 10x Genomics to advance the development of these resources to accelerate scientific discovery and advance our understanding of biology’s complexity." ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Shares of TXG opened at $7.14 on Tuesday. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $37.74. The stock’s fifty day moving average price is $10.96 and its two-hundred day moving ...

Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $12 from $15 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools ...

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers. The ...

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties 10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates ...

Arc Institute continues its work to generate and share large-scale, high-quality datasets of cell state before and after chemical or genetic perturbations to enable "virtual cell" models and other ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...